Clinical Trial

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-01-31; most recent amendment 2026-05-21.
Status change: Recruiting → Active, Not Recruiting 2025-11-19
Status change: Not Yet Recruiting → Recruiting 2025-03-14
Trial Details
NCT Number NCT06812325
Lead Sponsor Viridian Therapeutics, Inc.
Conditions Thyroid Eye Disease (TED)
Enrollment 320 participants
Start Date 2025-02-03
Primary Completion 2026-04-22 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-22